Skip to main content
Top
Published in: Breast Cancer Research 4/2014

Open Access 01-08-2014 | Research article

Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study

Authors: Kayo Togawa, Huiyan Ma, Jane Sullivan-Halley, Marian L Neuhouser, Ikuyo Imayama, Kathy B Baumgartner, Ashley Wilder Smith, Catherine M Alfano, Anne McTiernan, Rachel Ballard-Barbash, Leslie Bernstein

Published in: Breast Cancer Research | Issue 4/2014

Login to get access

Abstract

Introduction

Lymphedema is a potentially debilitating condition that occurs among breast cancer survivors. This study examines the incidence of self-reported lymphedema, timing of lymphedema onset, and associations between sociodemographic, clinical and lifestyle factors and lymphedema risk across racial-ethnic groups using data from a multicenter, multiethnic prospective cohort study of breast cancer survivors, the Health, Eating, Activity and Lifestyle Study.

Methods

A total of 666 women diagnosed with breast cancer staged as in situ, localized or regional disease at ages 35 to 64 years were recruited through the Surveillance, Epidemiology, and End Results registries in New Mexico (non-Hispanic white and Hispanic white), Los Angeles County (black), and Western Washington (non-Hispanic white) and followed for a median of 10.2 years. We evaluated sociodemographic factors, breast cancer- and treatment-related factors, comorbidities, body mass index (BMI), hormonal factors, and lifestyle factors in relation to self-reported lymphedema by fitting Cox proportional hazards models, estimating hazard ratios (HR) and 95% confidence intervals (CI).

Results

Over the follow-up period, 190 women (29%) reported lymphedema. The median time from breast cancer diagnosis to onset of lymphedema was 10.5 months (range: 0.5 to 134.9 months). Factors independently associated with lymphedema were total/modified radical mastectomy (versus partial/less than total mastectomy; HR = 1.37, 95% CI: 1.01 to 1.85), chemotherapy (versus no chemotherapy; HR = 1.48, 95% CI: 1.09 to 2.02), no lymph nodes removed (versus ≥10 lymph nodes removed; HR = 0.17, 95% CI: 0.08 to 0.33), pre-diagnostic BMI ≥30 kg/m2 (versus BMI <25 kg/m2; HR = 1.59, 95% CI: 1.09 to 2.31), and hypertension (versus no hypertension; HR = 1.49, 95% CI: 1.06 to 2.10). After adjusting for demographics and breast cancer- and treatment-related factors, no significant difference in lymphedema risk was observed across racial/ethnic groups. Analyses stratified by race/ethnicity showed that hypertension and chemotherapy were lymphedema risk factors only for black women.

Conclusions

Breast cancer patients who have undergone extensive surgery or extensive lymph node dissection, or who have a higher BMI should be closely monitored for detection and treatment of lymphedema. Further studies are needed to understand the roles of chemotherapy and hypertension in the development of lymphedema.
Appendix
Available only for authorised users
Literature
1.
go back to reference DiSipio T, Rye S, Newman B, Hayes S: Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013, 14: 500-515. 10.1016/S1470-2045(13)70076-7.CrossRefPubMed DiSipio T, Rye S, Newman B, Hayes S: Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013, 14: 500-515. 10.1016/S1470-2045(13)70076-7.CrossRefPubMed
2.
go back to reference Meeske KA, Sullivan-Halley J, Smith AW, McTiernan A, Baumgartner KB, Harlan LC, Bernstein L: Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat. 2008, 113: 383-391. 10.1007/s10549-008-9940-5.CrossRefPubMed Meeske KA, Sullivan-Halley J, Smith AW, McTiernan A, Baumgartner KB, Harlan LC, Bernstein L: Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat. 2008, 113: 383-391. 10.1007/s10549-008-9940-5.CrossRefPubMed
3.
go back to reference Norrmen C, Tammela T, Petrova TV, Alitalo K: Biological basis of therapeutic lymphangiogenesis. Circulation. 2011, 123: 1335-1351. 10.1161/CIRCULATIONAHA.107.704098.CrossRefPubMed Norrmen C, Tammela T, Petrova TV, Alitalo K: Biological basis of therapeutic lymphangiogenesis. Circulation. 2011, 123: 1335-1351. 10.1161/CIRCULATIONAHA.107.704098.CrossRefPubMed
4.
go back to reference Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006, 98: 599-609. 10.1093/jnci/djj158.CrossRefPubMed Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006, 98: 599-609. 10.1093/jnci/djj158.CrossRefPubMed
5.
go back to reference Nielsen I, Gordon S, Selby A: Breast cancer-related lymphoedema risk reduction advice: A challenge for health professionals. Cancer Treat Rev. 2008, 34: 621-628. 10.1016/j.ctrv.2007.11.002.CrossRefPubMed Nielsen I, Gordon S, Selby A: Breast cancer-related lymphoedema risk reduction advice: A challenge for health professionals. Cancer Treat Rev. 2008, 34: 621-628. 10.1016/j.ctrv.2007.11.002.CrossRefPubMed
6.
go back to reference Goyal A, Duley L, Fakis A: Axillary treatment for patients with early breast cancer and lymph node metastasis: systematic review protocol. World J Surg Oncol. 2013, 11: 6-10.1186/1477-7819-11-6.CrossRefPubMedPubMedCentral Goyal A, Duley L, Fakis A: Axillary treatment for patients with early breast cancer and lymph node metastasis: systematic review protocol. World J Surg Oncol. 2013, 11: 6-10.1186/1477-7819-11-6.CrossRefPubMedPubMedCentral
7.
go back to reference Petrek JA, Pressman PI, Smith RA: Lymphedema: current issues in research and management. CA Cancer J Clin. 2000, 50: 292-307. 10.3322/canjclin.50.5.292. quiz 308-11CrossRefPubMed Petrek JA, Pressman PI, Smith RA: Lymphedema: current issues in research and management. CA Cancer J Clin. 2000, 50: 292-307. 10.3322/canjclin.50.5.292. quiz 308-11CrossRefPubMed
8.
go back to reference Shih YCT, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS: Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009, 27: 2007-2014. 10.1200/JCO.2008.18.3517.CrossRefPubMed Shih YCT, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS: Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009, 27: 2007-2014. 10.1200/JCO.2008.18.3517.CrossRefPubMed
9.
go back to reference Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, Prieto Merino D, Mayoral del Moral O, Cerezo Tellez E, Minayo Mogollon E: Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010, 340: b5396-b5396. 10.1136/bmj.b5396.CrossRefPubMedPubMedCentral Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, Prieto Merino D, Mayoral del Moral O, Cerezo Tellez E, Minayo Mogollon E: Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010, 340: b5396-b5396. 10.1136/bmj.b5396.CrossRefPubMedPubMedCentral
10.
go back to reference Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ: Case 3. Upper limb lymphangiosarcoma following breast cancer therapy. J Clin Oncol. 2006, 24: 1477-1478. 10.1200/JCO.2005.01.8473.CrossRefPubMed Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ: Case 3. Upper limb lymphangiosarcoma following breast cancer therapy. J Clin Oncol. 2006, 24: 1477-1478. 10.1200/JCO.2005.01.8473.CrossRefPubMed
11.
go back to reference Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR: Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008, 26: 5689-5696. 10.1200/JCO.2008.16.4731.CrossRefPubMedPubMedCentral Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR: Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008, 26: 5689-5696. 10.1200/JCO.2008.16.4731.CrossRefPubMedPubMedCentral
12.
go back to reference Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM: The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007, 16: 775-782. 10.1158/1055-9965.EPI-06-0168.CrossRefPubMedPubMedCentral Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM: The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007, 16: 775-782. 10.1158/1055-9965.EPI-06-0168.CrossRefPubMedPubMedCentral
13.
go back to reference Kwan W: Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002, 20: 4242-4248. 10.1200/JCO.2002.09.018.CrossRefPubMed Kwan W: Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002, 20: 4242-4248. 10.1200/JCO.2002.09.018.CrossRefPubMed
14.
go back to reference Beaulac SM, McNair LA, Scott TE, LaMorte WW, Kavanah MT: Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002, 137: 1253-1257. 10.1001/archsurg.137.11.1253.CrossRefPubMed Beaulac SM, McNair LA, Scott TE, LaMorte WW, Kavanah MT: Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002, 137: 1253-1257. 10.1001/archsurg.137.11.1253.CrossRefPubMed
15.
go back to reference Dominick SA, Madlensky L, Natarajan L, Pierce JP: Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv. 2013, 7: 115-123. 10.1007/s11764-012-0251-9.CrossRefPubMed Dominick SA, Madlensky L, Natarajan L, Pierce JP: Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv. 2013, 7: 115-123. 10.1007/s11764-012-0251-9.CrossRefPubMed
16.
go back to reference Hayes SC, Janda M, Cornish B, Battistutta D, Newman B: Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008, 26: 3536-3542. 10.1200/JCO.2007.14.4899.CrossRefPubMed Hayes SC, Janda M, Cornish B, Battistutta D, Newman B: Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008, 26: 3536-3542. 10.1200/JCO.2007.14.4899.CrossRefPubMed
17.
go back to reference Kwan ML, Darbinian J, Schmitz KH, Citron R, Partee P, Kutner SE, Kushi LH: Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010, 145: 1055-1063. 10.1001/archsurg.2010.231.CrossRefPubMedPubMedCentral Kwan ML, Darbinian J, Schmitz KH, Citron R, Partee P, Kutner SE, Kushi LH: Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010, 145: 1055-1063. 10.1001/archsurg.2010.231.CrossRefPubMedPubMedCentral
18.
go back to reference Mak SS, Yeo W, Lee YM, Mo KF, Tse KY, Tse SM, Ho FP, Kwan WH: Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008, 57: 416-425. 10.1097/NNR.0b013e31818c3de2.CrossRefPubMed Mak SS, Yeo W, Lee YM, Mo KF, Tse KY, Tse SM, Ho FP, Kwan WH: Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008, 57: 416-425. 10.1097/NNR.0b013e31818c3de2.CrossRefPubMed
19.
go back to reference Geller BM, Vacek PM, O'Brien P, Secker-Walker RH: Factors associated with arm swelling after breast cancer surgery. J Womens Health (Larchmt). 2003, 12: 921-930. 10.1089/154099903770948159.CrossRef Geller BM, Vacek PM, O'Brien P, Secker-Walker RH: Factors associated with arm swelling after breast cancer surgery. J Womens Health (Larchmt). 2003, 12: 921-930. 10.1089/154099903770948159.CrossRef
20.
go back to reference Petrek JA, Senie RT, Peters M, Rosen PP: Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001, 92: 1368-1377. 10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9.CrossRefPubMed Petrek JA, Senie RT, Peters M, Rosen PP: Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001, 92: 1368-1377. 10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9.CrossRefPubMed
21.
go back to reference Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR: Breast cancer-related lymphedema-what are the significant predictors and how they affect the severity of lymphedema?. Breast J. 2006, 12: 536-543. 10.1111/j.1524-4741.2006.00342.x.CrossRefPubMed Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR: Breast cancer-related lymphedema-what are the significant predictors and how they affect the severity of lymphedema?. Breast J. 2006, 12: 536-543. 10.1111/j.1524-4741.2006.00342.x.CrossRefPubMed
22.
go back to reference Ahmed RL, Schmitz KH, Prizment AE, Folsom AR: Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat. 2011, 130: 981-991. 10.1007/s10549-011-1667-z.CrossRefPubMedPubMedCentral Ahmed RL, Schmitz KH, Prizment AE, Folsom AR: Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat. 2011, 130: 981-991. 10.1007/s10549-011-1667-z.CrossRefPubMedPubMedCentral
23.
go back to reference Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HAS, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ: Risk factors for lymphedema after breast cancer treatment. Canc Epidemiol Biomarkers Prev. 2010, 19: 2734-2746. 10.1158/1055-9965.EPI-09-1245.CrossRef Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HAS, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ: Risk factors for lymphedema after breast cancer treatment. Canc Epidemiol Biomarkers Prev. 2010, 19: 2734-2746. 10.1158/1055-9965.EPI-09-1245.CrossRef
24.
go back to reference Helyer LK, Varnic M, Le LW, Leong W, McCready D: Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010, 16: 48-54. 10.1111/j.1524-4741.2009.00855.x.CrossRefPubMed Helyer LK, Varnic M, Le LW, Leong W, McCready D: Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010, 16: 48-54. 10.1111/j.1524-4741.2009.00855.x.CrossRefPubMed
25.
go back to reference Herd-Smith AA, Russo AA, Muraca MGM, Del Turco MRM, Cardona GG: Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001, 92: 1783-1787. 10.1002/1097-0142(20011001)92:7<1783::AID-CNCR1694>3.0.CO;2-G.CrossRefPubMed Herd-Smith AA, Russo AA, Muraca MGM, Del Turco MRM, Cardona GG: Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001, 92: 1783-1787. 10.1002/1097-0142(20011001)92:7<1783::AID-CNCR1694>3.0.CO;2-G.CrossRefPubMed
26.
go back to reference Powell SN, Taghian AG, Kachnic LA, Coen JJ, Assaad SI: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003, 55: 1209-1215. 10.1016/S0360-3016(02)04273-6.CrossRefPubMed Powell SN, Taghian AG, Kachnic LA, Coen JJ, Assaad SI: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003, 55: 1209-1215. 10.1016/S0360-3016(02)04273-6.CrossRefPubMed
27.
go back to reference Ozaslan C, Kuru B: Lymphedema after treatment of breast cancer. Am J Surg. 2004, 187: 69-72. 10.1016/j.amjsurg.2002.12.003.CrossRefPubMed Ozaslan C, Kuru B: Lymphedema after treatment of breast cancer. Am J Surg. 2004, 187: 69-72. 10.1016/j.amjsurg.2002.12.003.CrossRefPubMed
28.
go back to reference Ridner SH, Dietrich MS, Stewart BR, Armer JM: Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer. 2011, 19: 853-857. 10.1007/s00520-011-1089-9.CrossRefPubMedPubMedCentral Ridner SH, Dietrich MS, Stewart BR, Armer JM: Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer. 2011, 19: 853-857. 10.1007/s00520-011-1089-9.CrossRefPubMedPubMedCentral
29.
go back to reference Clough-Gorr KM, Ganz PA, Silliman RA: Older breast cancer survivors: factors associated with self-reported symptoms of persistent lymphedema over 7 years of follow-up. Breast J. 2010, 16: 147-155. 10.1111/j.1524-4741.2009.00878.x.CrossRefPubMed Clough-Gorr KM, Ganz PA, Silliman RA: Older breast cancer survivors: factors associated with self-reported symptoms of persistent lymphedema over 7 years of follow-up. Breast J. 2010, 16: 147-155. 10.1111/j.1524-4741.2009.00878.x.CrossRefPubMed
30.
go back to reference Clark B, Sitzia J, Harlow W: Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM. 2005, 98: 343-348. 10.1093/qjmed/hci053.CrossRefPubMed Clark B, Sitzia J, Harlow W: Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM. 2005, 98: 343-348. 10.1093/qjmed/hci053.CrossRefPubMed
31.
go back to reference Edwards TLT: Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. ANZ J Surg. 2000, 70: 412-418. 10.1046/j.1440-1622.2000.01839.x.CrossRef Edwards TLT: Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. ANZ J Surg. 2000, 70: 412-418. 10.1046/j.1440-1622.2000.01839.x.CrossRef
32.
go back to reference Jammallo LS, Miller CL, Singer M, Horick NK, Skolny MN, Specht MC, O'Toole J, Taghian AG: Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Res Treat. 2013, 142: 59-67. 10.1007/s10549-013-2715-7.CrossRefPubMed Jammallo LS, Miller CL, Singer M, Horick NK, Skolny MN, Specht MC, O'Toole J, Taghian AG: Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Res Treat. 2013, 142: 59-67. 10.1007/s10549-013-2715-7.CrossRefPubMed
33.
34.
go back to reference Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R: Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003, 97: 1746-1757. 10.1002/cncr.11227.CrossRefPubMedPubMedCentral Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R: Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003, 97: 1746-1757. 10.1002/cncr.11227.CrossRefPubMedPubMedCentral
35.
go back to reference Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DRJ, Schmitz KH, Emplaincourt PO, Jacobs DRJ, Leon AS: Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000, 32: S498-S504. 10.1097/00005768-200009001-00009.CrossRefPubMed Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DRJ, Schmitz KH, Emplaincourt PO, Jacobs DRJ, Leon AS: Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000, 32: S498-S504. 10.1097/00005768-200009001-00009.CrossRefPubMed
36.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
37.
go back to reference Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, McTiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R: Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv. 2009, 3: 89-98. 10.1007/s11764-009-0084-3.CrossRefPubMedPubMedCentral Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, McTiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R: Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv. 2009, 3: 89-98. 10.1007/s11764-009-0084-3.CrossRefPubMedPubMedCentral
38.
go back to reference Alfano CM, McGregor BA, Kuniyuki A, Reeve BB, Bowen DJ, Baumgartner KB, Bernstein L, Ballard-Barbash R, Malone KE, Ganz PA, McTiernan A: Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psycho-Oncology. 2006, 15: 985-1000. 10.1002/pon.1033.CrossRefPubMedPubMedCentral Alfano CM, McGregor BA, Kuniyuki A, Reeve BB, Bowen DJ, Baumgartner KB, Bernstein L, Ballard-Barbash R, Malone KE, Ganz PA, McTiernan A: Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psycho-Oncology. 2006, 15: 985-1000. 10.1002/pon.1033.CrossRefPubMedPubMedCentral
39.
go back to reference Enderlein G, Cox DR, Oakes D: Analysis of survival data. Chapman and Hall, London - New York 1984, 201 S. Biom J. 1987, 29: 114-114. 10.1002/bimj.4710290119.CrossRef Enderlein G, Cox DR, Oakes D: Analysis of survival data. Chapman and Hall, London - New York 1984, 201 S. Biom J. 1987, 29: 114-114. 10.1002/bimj.4710290119.CrossRef
40.
go back to reference Gärtner R, Jensen M-B, Kronborg L, Ewertz M, Kehlet H, Kroman N: Self-reported arm-lymphedema and functional impairment after breast cancer treatment-a nationwide study of prevalence and associated factors. Breast. 2010, 19: 506-515. 10.1016/j.breast.2010.05.015.CrossRefPubMed Gärtner R, Jensen M-B, Kronborg L, Ewertz M, Kehlet H, Kroman N: Self-reported arm-lymphedema and functional impairment after breast cancer treatment-a nationwide study of prevalence and associated factors. Breast. 2010, 19: 506-515. 10.1016/j.breast.2010.05.015.CrossRefPubMed
41.
go back to reference Hayes SB, Freedman GM, Li T, Anderson PR, Ross E: Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation?. Int J Radiat Oncol Biol Phys. 2008, 72: 1449-1455. 10.1016/j.ijrobp.2008.02.080.CrossRefPubMed Hayes SB, Freedman GM, Li T, Anderson PR, Ross E: Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation?. Int J Radiat Oncol Biol Phys. 2008, 72: 1449-1455. 10.1016/j.ijrobp.2008.02.080.CrossRefPubMed
42.
go back to reference De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, Nuzzo F, Rossi E, D'Aiuto G, Capasso I, Rinaldo M, Morrica B, Elmo M, Di Maio M, Perrone F, de Matteis A: Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 2005, 5: 30-10.1186/1471-2407-5-30.CrossRefPubMedPubMedCentral De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, Nuzzo F, Rossi E, D'Aiuto G, Capasso I, Rinaldo M, Morrica B, Elmo M, Di Maio M, Perrone F, de Matteis A: Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 2005, 5: 30-10.1186/1471-2407-5-30.CrossRefPubMedPubMedCentral
43.
go back to reference Swystun LL, Mukherjee S, Levine M, Liaw PC: The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models. J Thromb Haemost. 2011, 9: 767-775. 10.1111/j.1538-7836.2011.04232.x.CrossRefPubMed Swystun LL, Mukherjee S, Levine M, Liaw PC: The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models. J Thromb Haemost. 2011, 9: 767-775. 10.1111/j.1538-7836.2011.04232.x.CrossRefPubMed
44.
go back to reference von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L: Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996, 14: 2560-2568.PubMed von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L: Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996, 14: 2560-2568.PubMed
45.
go back to reference Clahsen PCP, van de Velde CJC, Julien JPJ, Floiras JLJ, Mignolet FYF: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994, 12: 1266-1271.PubMed Clahsen PCP, van de Velde CJC, Julien JPJ, Floiras JLJ, Mignolet FYF: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994, 12: 1266-1271.PubMed
46.
go back to reference Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E: Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008, 100: 462-474. 10.1093/jnci/djn057.CrossRefPubMed Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E: Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008, 100: 462-474. 10.1093/jnci/djn057.CrossRefPubMed
47.
go back to reference Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ: Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009, 27: 390-397. 10.1200/JCO.2008.17.9291.CrossRefPubMedPubMedCentral Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ: Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009, 27: 390-397. 10.1200/JCO.2008.17.9291.CrossRefPubMedPubMedCentral
Metadata
Title
Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study
Authors
Kayo Togawa
Huiyan Ma
Jane Sullivan-Halley
Marian L Neuhouser
Ikuyo Imayama
Kathy B Baumgartner
Ashley Wilder Smith
Catherine M Alfano
Anne McTiernan
Rachel Ballard-Barbash
Leslie Bernstein
Publication date
01-08-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-014-0414-x

Other articles of this Issue 4/2014

Breast Cancer Research 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine